- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Granahan Investment Management Reduces Stake in Syndax Pharmaceuticals
Institutional investor cuts holdings by 60% in third quarter
Mar. 16, 2026 at 10:39am
Got story updates? Submit your updates here. ›
Granahan Investment Management LLC reduced its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 60.0% in the third quarter, according to the company's recent Form 13F filing with the SEC. The institutional investor owned 396,336 shares of the company's stock after selling 595,052 shares during the quarter.
Why it matters
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Institutional investor activity and changes in ownership stakes can provide insights into market sentiment and the perceived potential of the company's drug pipeline.
The details
Granahan Investment Management LLC reduced its position in Syndax Pharmaceuticals by selling 595,052 shares in the third quarter. The firm now owns 396,336 shares, or about 0.46% of the company's outstanding stock, worth approximately $6.1 million. Several other institutional investors have also recently added to or reduced their stakes in Syndax, including Brevan Howard Capital Management LP, Cinctive Capital Management LP, and Boothbay Fund Management LLC.
- Granahan Investment Management reduced its holdings in Syndax Pharmaceuticals in the third quarter of 2026.
The players
Granahan Investment Management LLC
An institutional investor that reduced its stake in Syndax Pharmaceuticals by 60% in the third quarter of 2026.
Syndax Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company focused on developing novel cancer therapies.
The takeaway
The reduction in Granahan Investment Management's stake in Syndax Pharmaceuticals suggests a potential shift in market sentiment or a reallocation of the firm's investment portfolio. However, the company's drug pipeline and ongoing clinical trials will continue to be closely watched by investors and analysts.
